Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: The FenOrli study

Current Medical Research and Opinion

Volumn 21, Issue 12, 2005, Pages 1997-2006

  Filippatos, T D ^a   Kiortsis, D N ^a   Liberopoulos, E N ^a,b   Georgoula, M ^a   Mikhailidis, D P ^b   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Fenofibrate; High density lipoprotein (HDL); Metabolic parameters; Metabolic syndrome; Obesity; Orlistat; Triglycerides

Indexed keywords

ALKALINE PHOSPHATASE; CHOLESTEROL; CREATININE; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TOLERABILITY; EDUCATION PROGRAM; ENZYME ACTIVITY; FECES INCONTINENCE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; LOW CALORY DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METABOLIC SYNDROME X; MORBID OBESITY; PRESCRIPTION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STEATORRHEA; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 29144456017     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X75078     Document Type: Article

References (61)

1. Le Gales-Camus C, Waxman A. Fighting obesity: clarification from World Health Organization. Br Med J 2004;329:53-4
2. McIntyre AM. Burden of illness review of obesity: are the true costs realised? J R Soc Health 1998;118:76-84
3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583-9
4. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004;55:589-612
5. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004;20:1691-701
6. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77
7. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41
8. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005;6:283-96
9. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for critical appraisal. Diabetes Care 2005;28:2289-304
10. Adult Treatment Panel III. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, final report. Circulation 2002;106:3143-421
11. Liberopoulos E, Tsouli S, Mikhailidis D, et al. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7 (in press)
12. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005;54:1065-74
13. Liberopoulos EN, Elisaf MS. Diagnosis of the metabolic syndrome: which definition should we use? Hell J Cardiol 2005;46:258-62
14. Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991;14:308-17
15. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005;31:15-22
16. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18:269-76
17. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, et al. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005;3:87-98
18. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin-resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995;92:1779-85
19. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-60
20. Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513-7
21. Steiner G. Fibrates in the metabolic syndrome and in diabetes. Endocrinol Metab Clin North Am 2004;33:545-55
22. UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 2004;20:241-7
23. Derosa G, Mugellini A, Ciccarelli L, et al. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003;25:1107-22
24. Bairaktari ET, Seferiadis KI, Elisaf MS. Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther 2005;10:45-54
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
26. Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001;25:1713-21
27. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003;91:961-4
28. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002;20:2257-67
29. Didangelos TP, Thanopoulou AK, Bousboulas SH, et al. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin 2004;20:1393-401
30. Reaven G, Segal K, Hauptman J, et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001;87:827-31
31. Mittendorfer B, Ostlund Jr RE, Patterson BW, et al. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9:599-604
32. Tolentino MC, Ferenczi A, Ronen L, et al. Combination of gemfibrozil and orlistat for treatment of combined hyperlipidaemia with predominant hypertriglyceridaemia. Endocr Pract 2002;8:208-12
33. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem 2005;12:1931-45
34. Wysocki J, Belowski D, Kalina M, et al. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther 2004;42:212-7
35. Idzior-Walus B, Sieradzki J, Rostworowski W, et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000;30:871-8
36. Kiortsis DN, Elisaf MS. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment. Fundam Clin Pharmacol 2001;15:401-3
37. Tsimihodimos V, Kostoula A, Kakafika A, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride levels. J Cardiovasc Pharmacol Ther 2004;9:27-33
38. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005;21:457-68
39. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients [European Multicentre Orlistat Study Group]. Lancet 1998;352:167-72
40. Davidson MH, Hauptman J, Di Girolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. J Am Med Assoc 1999;281:235-42
41. Poobalan A, Aucott L, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term lipid outcomes - a systematic review. Obes Rev 2004;5:43-50
42. Sartorio A, Lafortuna CL, Vangeli V, et al. Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program. Eur J Clin Nutr 2001;55:865-9
43. Noakes M, Keogh JB, Foster PR, et al. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005;81:1298-306
44. McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002;10:642-50
45. Brook RD, Bard RL, Glazewski L, et al. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am J Cardiol 2004;93:1012-6
46. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288-94
47. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123-8
48. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002;25:1033-41
49. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61
50. Tsimihodimos V, Miltiadous G, Bairaktari E, et al. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol 2002;57:407-8
51. Wierzbicki AS, Nishtar S, Lumb PJ, et al. Impaired renal function and atherosclerosis in a Pakistani cohort. Curr Med Res Opin 2005;21:1201-7
52. Athyros VG, Elisaf M, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
53. Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002;20:347
54. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, et al. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005;11 (in press)
55. Feher MD, Hepburn AL, Hogarth MB, et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003;42:321-5
56. Hepburn AL, Kaye SA, Feher MD. Long-term remission from gout associated with fenofibrate therapy. Clin Rheumatol 2003;22:73-6
57. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421-7
58. Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004;23:131-4
59. Ganotakis E, Tsimihodimos V, Bairaktari E, et al. Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis 2002;165:187-8
60. Rizos E, Bairaktari E, Ganotakis E, et al. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002;7:219-26
61. Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease: a clinical-histological study. J Hepatol 2004;41:751-7